GLP-1 Receptor Agonist-Induced Muscle Mass Evaluation and Retention
Latest Information Update: 24 Jul 2026
At a glance
- Drugs Semaglutide (Primary) ; Semaglutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms GLIMMER
Most Recent Events
- 20 Apr 2026 Planned initiation date changed from 1 Feb 2026 to 14 Apr 2026.
- 20 Apr 2026 Status changed from not yet recruiting to recruiting.
- 21 Jan 2026 Planned number of patients changed from 25 to 50.